How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side ...

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

They are composed of a lipid core stabilized by surfactants or other agents ... are also being refined to scale up production while maintaining quality. 5 Integrating liposome technology with ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying ...

Transaction eliminates $11.2 million in debt, strengthening financial position -HUNTSVILLE, AL, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Serina ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...

How can we ensure that life-saving drugs or genetic therapies reach their intended target cells without causing harmful side ...